A kit and a detection method for detecting wild strains and vaccine strains of Brucella

Through the colloidal gold strip kit that binds crRNA and crDNA, using RPA amplification and CRISPR systems, the problem of the inability to distribute wild strains and vaccine strains of Ruthenia in the prior art is solved, and efficient and specific detection is achieved , suitable for the prevention and control of brucellosis.

CN116042879BActive Publication Date: 2024-11-26INNER MONGOLIA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310045360.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-30
Publication Date
2024-11-26
Estimated Expiration
2043-01-30

AI Technical Summary

Technical Problem

The existing Brucella detection methods cannot distinguish and identify wild strains and vaccine strains. The traditional methods are inefficient, not specific, and require professional personnel to operate and expensive instruments.

Method used

Using the colloidal gold strip kit that binds crRNA and crDNA, the RPA amplification technology and the CRISPR system was used to identify DNA transcripts using Cas13a protein and specific crRNA to form a colloidal gold strip to distinguish wild strains and vaccine strains.

Benefits of technology

It realizes rapid, sensitive and highly specific detection, can distinguish within one hour, and is simple to operate, suitable for the prevention and control of brucellosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure HDA0004055171630000011
    Figure HDA0004055171630000011
Patent Text Reader

Abstract

The present invention relates to a kit and a detection method for detecting wild strains and vaccine strains of Brucella. The kit includes crRNA, and the crRNA is a combination of crRNA (WT) and crRNA (Vac), and the sequence of crRNA (WT) is shown in SEQ ID NO.1, and the sequence of crRNA (Vac) is shown in SEQ ID NO.2. Or crRNA is obtained by transcription of crDNA (WT) and crDNA (Vac), and the crDNA sequence is shown in SEQ ID NO.3 and SEQ ID NO.4. The present invention performs genome bioinformatics analysis and difference analysis comparison on wild strains of Brucella or Brucella S2 vaccine strains, and finds that there are significant differences between wild strains of Brucella or Brucella S2 vaccine strains. Then crRNA is designed according to the difference, and it is realized that only one test strip is used to distinguish whether the sample to be tested is a wild strain of Brucella or a S2 vaccine strain of Brucella, which effectively solves the problem of identifying and distinguishing S2 vaccine strains and wild strains in the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a kit and a detection method for detecting wild strains and vaccine strains of Brucella, belonging to the technical field of biological detection. Background Art

[0002] Brucellosis is a zoonotic systemic infectious disease caused by Brucella infection. It is also known as Mediterranean remittent fever, Malta fever, and undulant fever. Brucella has a wide range of hosts and is highly contagious. Different species of Brucella have the ability to cross-infect one host, posing a serious threat to animal husbandry and human health.

[0003] Brucella is a Gram-negative, non-motile bacterium with no capsule (the smooth type has a microcapsule), catalase and oxidase positive, an absolute aerobic bacterium, capable of reducing nitrates, and an intracellular parasite that can survive in many types of livestock. Brucella is widely distributed throughout the world. According to surveys, 170 countries and regions around the world have reported cases of brucellosis. Human brucellosis is also on the rise. The epidemic of human brucellosis shows obvious occupational, regional, and seasonal characteristics. Human brucellosis may be related to contact with infected animals. Therefore, animal brucellosis must be fundamentally prevented and controlled.

[0004] On the one hand, traditional pathogen isolation and culture, serological detection technology and molecular biological detection methods have many limitations, such as the cumbersome, long cycle and low efficiency of conventional biochemical identification process; low specificity of immune detection, which is easy to cause missed detection; RT-PCR is time-consuming, cumbersome, expensive and inconvenient to carry and requires professional personnel to operate. On the other hand, although the existing Brucella test kit can detect Brucella, it cannot distinguish and identify Brucella wild strains and vaccine strains. Therefore, it is urgent to develop a test kit that can detect Brucella wild strains and vaccine strains. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a kit and a detection method for detecting wild strains and vaccine strains of Brucella.

[0006] The technical solution of the present invention is as follows:

[0007] A crRNA for detecting wild strains and / or vaccine strains of Brucella, wherein the crRNA is a combination of crRNA (WT) and crRNA (Vac);

[0008] The sequence of the crRNA (WT) is shown in SEQ ID NO.2; the sequence of the crRNA (Vac) is shown in SEQ ID NO.1.

[0009] A crDNA for detecting wild strains and / or vaccine strains of Brucella, wherein the crDNA is a combination of crDNA (WT) and crDNA (Vac);

[0010] The sequence of the crDNA (WT) is shown in SEQ ID NO.4; the sequence of the crDNA (Vac) is shown in SEQ ID NO.3.

[0011] A DNA for detecting wild strains and / or vaccine strains of Brucella, wherein the DNA is a combination of DNA (WT) and DNA (Vac);

[0012] The sequence of the DNA (WT) is shown as SEQ ID NO.6; the sequence of the DNA (Vac) is shown as SEQ ID NO.5.

[0013] The crRNA (WT) and crRNA (Vac) can be obtained by artificial synthesis, or transcribed using crDNA (WT) and crDNA (Vac) as templates, wherein the DNA (WT) is the targeting sequence of crRNA (WT), and the DNA (Vac) is the targeting sequence of crRNA (Vac), and are used to detect and distinguish between wild strains of Brucella and Brucella S2 vaccine strains.

[0014] A kit for detecting wild strains and / or vaccine strains of Brucella, characterized in that it comprises the above-mentioned crRNA or crDNA.

[0015] Preferably according to the present invention, the kit is a colloidal gold test strip kit.

[0016] Further preferably, the colloidal gold test strip kit includes Cas13a protein and a colloidal gold test strip; the colloidal gold test strip includes a base plate, and a sample pad, a connection pad, a nitrocellulose membrane and an absorption pad sequentially connected and attached to the base plate; a first detection line and a second detection line are arranged on the nitrocellulose membrane; a TAMRA ligand is fixed on the first detection line, and a Biotin ligand is fixed on the second detection line.

[0017] A method for detecting and identifying wild strains and / or vaccine strains of Brucella using the above kit for non-diagnostic purposes comprises the following steps:

[0018] (1) Extracting the genome of the sample to be tested;

[0019] (2) The extracted genome of the sample to be tested is used as a template and added to a reaction system containing a reaction solution and a polymerase for RPA amplification;

[0020] (3) Taking the RPA amplification products and establishing the first detection system and the second detection system respectively, incubating at 37° C. for 10 to 60 min;

[0021] (4) The first detection system and the second detection system are mixed evenly in equal volumes, and then enzyme-free water is added to obtain a reaction solution, and then the reaction solution is dropped onto the test strip. After 5 to 10 minutes, when there is no band on the first detection line and there is a band on the second detection line, it indicates that the sample to be tested is a wild strain; when there is a band on the first detection line and there is no band on the second detection line, it indicates that the sample to be tested is an S2 vaccine strain; when there are bands on both the first detection line and the second detection line, it indicates that the sample to be tested is not infected with Brucella.

[0022] Preferably, according to the present invention, in step (1), the sample to be tested is whole blood, urine or saliva of sheep, cattle and pigs that has been pre-inactivated at 65-80° C. for 10 minutes.

[0023] Preferably according to the present invention, in step (2), the primer sequence for RPA amplification is:

[0024] Forward Primer:

[0025] 5'-GAAATTAATACGACTCACTATAGGGCTGCGTCAGCCCGCCATCCACACTCGCCA G-3';

[0026] Reverse primer: 5′-TTGCGGGTGGTTATTCCTTTCACCCTTTAC-3′.

[0027] Preferably, in step (2) of the present invention, the RPA amplification system is: one tube of RPA basic reaction ball, 29.5 μL of rehydration buffer, 2.5 μL of magnesium acetate buffer, 2.5 μL of forward primer, 2.5 μL of reverse primer, and the rest is supplemented with 8 μL of enzyme-free water, and then distributed into 5 equal portions, each of 9 μL, and 1 μL of the sample to be tested is added to each portion, with a total volume of 10 μL.

[0028] The amplification conditions are: reaction temperature 39-42°C, incubation time 5-20 min.

[0029] Among them, RPA basic reaction ball, rehydration buffer and magnesium acetate buffer are all from TwistAmp R Basic kit, the RPA basic reaction ball is a spherical solid containing recombinase, polymerase and other components.

[0030] Preferably according to the present invention, in step (3), the first detection system is: Tris-HCl (400mM), MgCl2 (120mM), T7 Polymerase 0.5μL, rNTP 0.8μL, reporter1 (1μM), crRNA (WT) 1μL, RNaseInhibitor 1μL, Cas13a protein 1μL, RPA amplification product 1μL, total volume 20μL; the reporter1 is 5'-DIG-UUUUUUUUUUUUUU-TAMRA-3';

[0031] The second detection system is: Tris-HCl (400mM), MgCl2 (120mM), reporter2 (1μM), crRNA (Vac) 1μL, RNase Inhibitor 1μL, Cas13a protein 2μL, T7 Polymerase 0.5μL, rNTP 0.8μL, RPA amplification product 1μL, total volume 20μL; the reporter2 is 5'-FAM-UUUUUUUUUUUUUU-Biotin-3'.

[0032] Preferably according to the present invention, in step (4), the volume ratio of the enzyme-free water to the first detection system is 1:3.

[0033] Everything not described in detail in the present invention is prior art.

[0034] The technical features of the present invention are as follows:

[0035] The Cas13a protein in the first detection system of the present invention is combined with crRNA (WT) to form a Cas13a-crRNA (WT) complex, which can specifically identify the transcription product of DNA (WT) in the RPA amplification product. If there is a DNA (WT) fragment in the RPA amplification product, the Cas13a protein is activated, and the reporter1 reporting group is cut, and the cut reporter1 reporting group cannot form a display band with the first detection line colloidal gold, that is, the first detection line has no band and the second detection line has a band, indicating that the sample to be tested is a wild strain. If there is no DNA (WT) fragment in the RPA amplification product, the Cas13a protein will not be activated, and the reporter1 reporting group is combined with colloidal gold and a ligand to form a display band, indicating that the sample to be tested is negative, not a wild strain. The Cas13a protein in the second detection system is combined with crRNA (Vac) to form a Cas13a-crRNA (Vac) complex, which can specifically identify the transcription product of DNA (Vac) in the RPA amplification product. If there is a DNA (Vac) fragment in the RPA amplification product, the Cas13a protein is activated, and the reporter2 reporter group is cut. The cut reporter2 reporter group cannot form a display band with the second detection line colloidal gold, that is, when the first detection line has a band and the second detection line has no band, it indicates that the sample to be tested is the S2 vaccine strain. If there is no DNA (WT) and DNA (Vac) fragment in the RPA amplification product, Cas13a will not be activated, and the reporter group is combined with the detection line colloidal gold and the ligand, that is, when the first detection line and the second detection line have bands, it indicates that the sample to be tested does not have Brucella infection.

[0036] Beneficial effects:

[0037] 1. The kit for detecting wild strains and / or vaccine strains of Brucella provided by the present invention can distinguish whether the sample to be tested is a wild strain of Brucella or a Brucella S2 vaccine strain with only one test strip, which effectively solves the problem of identifying and distinguishing S2 vaccine strains and wild strains in the prior art. In addition, the detection method provided by the present invention has strong specificity, low detection limit, high sensitivity, good color development effect, short detection cycle, and can be visible to the naked eye compared with the traditional detection method.

[0038] 2. The detection method provided by the present invention combines the RPA amplification technology with the CRISPR system, reduces mutual interference through reasonable ratio, enables the reaction reagents to still accurately and specifically realize their respective functions, combines amplification and detection, and can also combine the high sensitivity of the RPA amplification technology with the high specificity of the CRISPR detection technology. The entire detection process takes a short time and can be completed within one hour. The operation steps are simple, providing a new idea and method for the purification of brucellosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is a graph showing the results of differential gene analysis.

[0040] Figure 2 This is the result of using the colloidal gold test strip kit to detect gradient concentrations of wild strains and vaccine strains. DETAILED DESCRIPTION

[0041] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.

[0042] Cas13a protein in the following examples, Beijing Kexin Biotechnology Co., Ltd.

[0043] TwistAmp R Basic kit, available from TwistDx-Merray (Shanghai) Biotechnology Co., Ltd.

[0044] The WT represents the wild type strain, and the Vac represents the vaccine strain.

[0045] Example 1. Design and acquisition of crRNA and DNA for detecting Brucella

[0046] Log in to NCBI and download gene sequences from GenBank, including Brucella vaccine strain S2, representative strains of Brucella wild strains (M28, ATCC23457, NI, BmWS93, CIT31, B9, QH61, BY38, 20236, RM57, Rev.1, A13334, 2308, 9-941, 104M, BD, BAB8416, clpP, MC, BJ1, 1330, QH05, CVI-71), etc., for genome bioinformatics analysis and difference analysis comparison. The analysis results are shown in the following table. Figure 1 shown.

[0047] Depend on Figure 1It is known that there are significant differences between the gene sequences of Brucella vaccine strain S2 and Brucella wild strains. The inventors of the present application further found that the gene loci for detecting and distinguishing Brucella vaccine strain S2 and Brucella wild strains are DNA (WT) and DNA (Vac) as shown in SEQ ID NO.6 and SEQ ID NO.5. It is known that Brucella vaccine strain S2 has 25 base deletions after 100bp compared to the representative strain of Brucella wild strains. The specific bases of the deletion are then related to the Brucella wild strain species ( Figure 1 ).

[0048] Then, based on the differences in the gene sequences of DNA (WT) and DNA (Vac), crRNA (WT) and crRNA (Vac) were designed, and their sequences are shown in SEQ ID NO.2 and SEQ ID NO.1, respectively. The crRNA (WT) and crRNA (Vac) designed by the present invention can specifically match the difference fragments of the gene regions of the wild strain and the S2 vaccine strain, thereby activating the corresponding Cas protein nuclease activity and cutting the reporter group in the system.

[0049] The specific operation method for obtaining crRNA is as follows: using crDNA as a template, annealing reaction is performed to form double-stranded DNA, followed by agarose gel electrophoresis, gel recovery and purification of DNA fragments, transcription to generate RNA under the action of T7 RNA polymerase, recovery and purification to obtain mature crRNA, and the purified crRNA is packaged and frozen at -80°C; or it can be directly synthesized artificially according to the sequence.

[0050] Among them, the sequence of crDNA (WT) is shown in SEQ ID NO.4; the sequence of crDNA (Vac) is shown in SEQ ID NO.3; the crDNA can be directly synthesized artificially according to the sequence.

[0051] Annealing system: Prepare the DNA oligo (synthetic primer) to be annealed into 50 μM using sterilized enzyme-free water or redistilled water.

[0052] Dissolve Annealing Buffer for DNA Oligos (5×), mix well and set aside.

[0053]

[0054]

[0055] Add various reagents in the order above and mix well.

[0056] The sequence of T7 primer is: 5'-GAAATTAATACGACTCACTATAGGG-3'.

[0057] Set up the PCR instrument for the annealing reaction as follows:

[0058]

[0059] The transcription system was as follows: 1 μg of template DNA, 2 μL of T7 RNA polymerase mixture, 10 μL of NTP Buffer Mix, and supplemented with enzyme-free water to a total volume of 30 μL.

[0060] The transcription conditions were: 37°C, 16h.

[0061] Example 3: Colloidal gold test strip kit for detecting wild strains and / or vaccine strains of Brucella

[0062] The kit of this embodiment includes a colloidal gold test strip, a colloidal gold test strip card, a microporous cup, a TwistAmp R Basic kit, crRNA (WT) and crRNA (Vac) (SEQ ID NO.1-2) for detecting and identifying wild strains and vaccine strains of Brucella, Cas13a protein, RPA amplification primers, Tris-HCl (400mM), MgCl2 (120mM), RNase Inhibitor, reporter1 (1μM), reporter2 (1μM), T7 Polymerase, and rNTP.

[0063] The colloidal gold test strip comprises a bottom plate, and a sample pad, a connection pad, a nitrocellulose membrane and an absorption pad which are sequentially connected and attached to the bottom plate; a first detection line and a second detection line are arranged on the nitrocellulose membrane. A TAMRA ligand is fixed on the first detection line, and a Biotin ligand is fixed on the second detection line.

[0064] The reporter1 is 5'-DIG-UUUUUUUUUUUUU-TAMRA-3';

[0065] The reporter2 is 5'-FAM-UUUUUUUUUUUUUU-Biotin-3'.

[0066] Example 4: Method for Brucella colloidal gold test strip detection using the kit described in Example 3

[0067] 20 μL of blood samples containing Brucella suis, Brucella melitensis and S2 vaccine strain were taken for Brucella colloidal gold test strip detection.

[0068] The specific method includes the following steps:

[0069] (1) The samples to be tested were pre-inactivated at 80°C for 10 minutes, and then 20 μL of NP-40 lysis buffer was added, shaken for 15 seconds to mix, and placed in a thermostat at 95-99°C for 10 minutes to obtain the genomes of the three samples to be tested;

[0070] (2) The extracted genome of the sample to be tested is used as a template and added to a reaction system containing a reaction solution and RPA to amplify the nucleic acid of the target gene;

[0071] RPA amplification reaction system: one tube of RPA basic reaction ball, 29.5μL rehydration buffer, 2.5μL magnesium acetate buffer, 2.5μL forward primer, 2.5μL reverse primer, and the rest is supplemented with 8μL enzyme-free water, with a total volume of 45μL, which is then distributed into 5 equal portions, each of 9μL, and 1μL of the sample to be tested is added to each portion. The RPA reaction of five samples can be amplified simultaneously, and the volume of each reaction is 10μL.

[0072] Amplification conditions were: reaction temperature 40°C, incubation time 15 min.

[0073] The RPA basic reaction ball, rehydration buffer and magnesium acetate buffer are all from TwistAmp R Basic kit.

[0074] The RPA amplification primers are selected from the following primer pairs:

[0075] Forward Primer:

[0076] 5'-GAAATTAATACGACTCACTATAGGGCTGCGTCAGCCCGCCATCCACACTCGCCA G-3';

[0077] Reverse primer: 5′-TTGCGGGTGGTTATTCCTTTCACCCTTTAC-3;

[0078] RPA amplification conditions: reaction temperature 40°C, incubation time 10 min;

[0079] Among them, RPA basic reaction ball, PBS buffer and magnesium acetate buffer are all from TwistAmp R Basic kit; RPA amplification is an existing technology;

[0080] The extracted genome was then diluted in a concentration gradient of: 10 6 copies / μL, 10 5 copies / μL, 10 4copies / μL, 10 3 copies / μL, 10 2 copies / μL, 10 1 copies / μL, and enzyme-free water was used as the control group (10 0 copy / μL) to obtain gradient concentrations of RPA amplification products;

[0081] (3) Taking gradient concentrations of RPA amplification products to establish the first detection system and the second detection system, respectively, and incubating at 37°C for 40 min;

[0082] The first detection system is: Tris-HCl (400mM), MgCl2 (120mM), T7 Polymerase 0.5μL, rNTP 0.8μL, reporter1 (0.1μM), crRNA (WT) 1μL, RNase Inhibitor 1μL, Cas13a protein 1μL, RPA amplification product 1μL, and a total volume of 20μL.

[0083] The second detection system is: Tris-HCl (400mM), MgCl2 (120mM), reporter2 (2μM), crRNA (Vac) 1μL, RNase Inhibitor 1μL, Cas13a protein 2μL, T7 Polymerase 0.5μL, rNTP 0.8μL, RPA amplification product 1μL, and a total volume of 20μL.

[0084] Among them, reporter1 is 5′-DIG-UUUUUUUUUUUUUU-TAMRA-3′;

[0085] reporter2 is 5'-FAM-UUUUUUUUUUUUU-Biotin-3'.

[0086] (4) 20 μL of the first detection system and 20 μL of the second detection system were mixed evenly, and 60 μL of enzyme-free water was added to obtain a reaction solution. The reaction solution was then dropped into the microporous cup to allow the reaction solution to be absorbed by the sample pad and flow to the first detection line and the second detection line in turn. After 10 minutes, the test result was obtained.

[0087] The test results of this embodiment are as follows Figure 2 As shown. Figure 2It can be seen that the test results of blood samples without S2 vaccine strains and wild strain genomes are that both the first test line and the second test line show bands; the test results of blood samples with S2 vaccine strains and no wild strain genomes are that the first test line shows bands, and the second test line does not show bands; the test results of blood samples without S2 vaccine strains and with wild strain genomes are that the first test line does not show bands, and the second test line shows bands. Figure 2 It shows that the detection line of the colloidal gold test strip is 10 1 -10 2 copies / μL, high sensitivity, low price, simple and fast operation, and easy to carry.

Claims

1. A crRNA for detecting wild strains and / or vaccine strains of Brucella, characterized in that, The crRNA is a combination of crRNA (WT) and crRNA (Vac); The sequence of the crRNA (WT) is shown in SEQ ID NO.2; the sequence of the crRNA (Vac) is shown in SEQ ID NO.

1.

2. A crDNA for detecting wild strains and / or vaccine strains of Brucella, characterized in that: The crDNA is a combination of crDNA (WT) and crDNA (Vac); The sequence of the crDNA (WT) is shown in SEQ ID NO.4; the sequence of the crDNA (Vac) is shown in SEQ ID NO.

3.

3. A kit for detecting wild strains and / or vaccine strains of Brucella, characterized in that: Comprising the crRNA of claim 1 or the crDNA of claim 2.

4. The kit for detecting wild strains of Brucella and / or vaccine strains as claimed in claim 3, characterized in that, The kit is a colloidal gold test strip kit; the colloidal gold test strip kit comprises Cas13a protein and a colloidal gold test strip.

5. The kit for detecting wild strains and / or vaccine strains of Brucella as claimed in claim 4, characterized in that, The colloidal gold test strip comprises a base plate, and a sample pad, a connection pad, a nitrocellulose membrane and an absorption pad which are sequentially connected and attached to the base plate; a first detection line and a second detection line are arranged on the nitrocellulose membrane; a TAMRA ligand is fixed on the first detection line, and a Biotin ligand is fixed on the second detection line.

6. A method for detecting and identifying wild strains and / or vaccine strains of Brucella for non-diagnostic purposes using the kit described in any one of claims 3 to 5, characterized in that: The steps include: (1) Extract the genome of the sample to be tested; (2) The extracted genome of the sample to be tested is used as a template and added to a reaction system containing a reaction solution and a polymerase for RPA amplification; Wherein, the primer sequence of the RPA amplification is: Forward Primer: 5'-GAAATTAATACGACTCACTATAGGGCTGCGTCAGCCCGCCATCCACACTCGCCA G-3'; Reverse primer: 5′-TTGCGGGTGGTTATTCCTTTCACCCTTTAC-3′; The RPA amplification system is: one tube of RPA basic reaction ball, 29.5 μL of rehydration buffer, 2.5 μL of magnesium acetate buffer, 2.5 μL of forward primer, 2.5 μL of reverse primer, and the rest is supplemented with 8 μL of enzyme-free water, and then distributed into 5 equal portions, each with 9 μL, and 1 μL of the sample to be tested is added to each portion, with a total volume of 10 μL; Amplification conditions were as follows: reaction temperature 39-42°C, incubation time 5-20 min; (3) Take the RPA amplification product to establish the first detection system and the second detection system respectively, and incubate at 37°C for 10-60 min; The first detection system is: Tris-HCl 400mM, MgCl2 120mM, T7 Polymerase 0.5μL, rNTP 0.8μL, reporter1 0.1μM, crRNA (WT) 1μL, RNase Inhibitor 1 μL, Cas13a protein 1μL, RPA amplification product 1 μL, total volume 20μL; The reporter1 is 5'-DIG-UUUUUUUUUUUUU-TAMRA-3'; The second detection system is: Tris-HCl 400mM, MgCl2 120mM, reporter2 2μM, crRNA (Vac) 1μL, RNase Inhibitor 1μL, Cas13a protein 2μL, T7 Polymerase 0.5μL, rNTP 0.8μL, RPA amplification product 1μL, total volume 20μL; The reporter2 is 5'-FAM-UUUUUUUUUUUUUU-Biotin-3'; (4) The first detection system and the second detection system are mixed evenly in equal volumes, and then enzyme-free water is added to obtain a reaction solution, and then the reaction solution is dropped onto the test strip. After 5 to 10 minutes, when there is no band on the first detection line and there is a band on the second detection line, it indicates that the sample to be tested is a wild strain; when there is a band on the first detection line and there is no band on the second detection line, it indicates that the sample to be tested is an S2 vaccine strain; when there are bands on both the first detection line and the second detection line, it indicates that the sample to be tested is not infected with Brucella; Wherein, the volume ratio of the enzyme-free water to the first detection system is 1:

3.

7. The method according to claim 6, characterized in that In step (1), the sample to be tested is whole blood, urine or saliva of sheep, cattle and pigs that has been pre-inactivated at 65-80°C for 10 minutes.